ArticleRheumatology (Oxford, England)2026
Assessing the mortality burden after acute myocardial infarction in SLE: insights from the MINAP Registry.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesAcute myocardial infarction (AMI) is a leading cause of mortality globally. Although SLE is known to increase the risk of AMI, its impact on long-term outcomes following AMI in contemporary populations remains poorly defined. To determine whether individuals with SLE experience higher long-term mortality after AMI compared with those without SLE.
methodsAdults hospitalized with AMI between January 2005 and March 2019 were identified from the Myocardial Ischaemia National Audit Project registry and linked with Hospital Episode Statistics and Office for National Statistics mortality records. Long-term all-cause and cardiovascular mortality were assessed up to 5 years post-AMI.
resultsOf 784 091 patients with AMI, 715 (0.1%) had a diagnosis of SLE. Patients with SLE were younger (median 63.9 vs 70.3 years; P < 0.001) and more often female (76% vs 34%; P < 0.001). Adjusted all-cause mortality was higher among those with SLE from 30 days (HR 1.62; 95% CI 1.23, 2.12; P = 0.001) to 5 years (HR 1.84; 95% CI 1.63, 2.09; P < 0.001). Adjusted cardiovascular mortality was similarly elevated at 30 days (HR 1.63; 95% CI 1.20-2.21; P = 0.002) and 5 years (HR 1.75; 95% CI 1.46-2.10; P < 0.001).
conclusionsIndividuals with SLE have a persistently higher risk of all-cause and cardiovascular mortality following AMI, despite being younger and having less traditional cardiovascular comorbidities. These findings highlight SLE as an independent determinant of adverse post-AMI outcomes and support aggressive, guideline-directed secondary prevention in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.